IQVIA (NYSE:IQV) Updates FY 2026 Earnings Guidance

IQVIA (NYSE:IQV) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 12.550-12.850 for the period, compared to the consensus estimate of 12.480. The company issued revenue guidance of $17.2 billion-$17.4 billion, compared to the consensus revenue estimate of $17.1 billion.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on IQV shares. Barclays set a $230.00 price objective on IQVIA in a research report on Monday, December 15th. Hsbc Global Res raised IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th. TD Cowen lifted their price target on shares of IQVIA from $215.00 to $245.00 and gave the stock a “hold” rating in a research note on Thursday, January 22nd. Evercore ISI boosted their price objective on shares of IQVIA from $220.00 to $240.00 and gave the stock an “outperform” rating in a report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. increased their target price on shares of IQVIA from $177.00 to $255.00 and gave the company an “overweight” rating in a report on Wednesday, October 29th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $251.06.

IQVIA Trading Down 0.6%

NYSE:IQV opened at $202.56 on Thursday. The firm has a market capitalization of $34.50 billion, a P/E ratio of 27.79, a P/E/G ratio of 2.07 and a beta of 1.37. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. The company has a fifty day moving average of $229.85 and a 200 day moving average of $209.62. IQVIA has a 52 week low of $134.65 and a 52 week high of $247.04.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The business’s revenue was up 10.3% compared to the same quarter last year. During the same period last year, the firm posted $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, research analysts predict that IQVIA will post 10.84 earnings per share for the current year.

Hedge Funds Weigh In On IQVIA

Hedge funds and other institutional investors have recently made changes to their positions in the business. Private Advisor Group LLC boosted its holdings in IQVIA by 1.0% in the third quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock valued at $1,163,000 after acquiring an additional 63 shares in the last quarter. E Fund Management Co. Ltd. lifted its position in shares of IQVIA by 3.7% in the 2nd quarter. E Fund Management Co. Ltd. now owns 2,099 shares of the medical research company’s stock worth $331,000 after purchasing an additional 74 shares during the period. Ancora Advisors LLC boosted its stake in shares of IQVIA by 17.9% during the 3rd quarter. Ancora Advisors LLC now owns 521 shares of the medical research company’s stock valued at $99,000 after purchasing an additional 79 shares in the last quarter. Quadrant Capital Group LLC increased its position in shares of IQVIA by 1.7% during the third quarter. Quadrant Capital Group LLC now owns 4,732 shares of the medical research company’s stock valued at $899,000 after buying an additional 81 shares during the period. Finally, Snowden Capital Advisors LLC raised its stake in IQVIA by 5.3% in the second quarter. Snowden Capital Advisors LLC now owns 2,364 shares of the medical research company’s stock worth $373,000 after buying an additional 120 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.